Overview

Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma

Status:
Not yet recruiting

Trial end date:
2024-07-31

Target enrollment:

Participant gender:

Summary

to learn if the combination of atezolizumab and tiragolumab can help to control bladder cancer when it is given before surgery to remove the bladder and tumor.

Phase:

Early Phase 1

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Treatments:

Atezolizumab